Skip to main content
S

SCL Science Inc. — Investor Relations & Filings

Ticker · 246960 ISIN · KR7246960009 KO Professional, scientific and technical activities
Open in API
Filings indexed 309 across all filing types
Latest filing 2024-08-09 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 246960

About SCL Science Inc.

https://sclscience.com/en

SCL Science Inc., formerly InnoTherapy Inc., is a healthcare company focused on digital innovation and advanced medical technologies. The company develops and commercializes medical hemostatic agents based on its proprietary biomimetic technology, including the Bio-inspired Medical Materials (BiMM) product line. Leveraging 40 years of expertise in medical science, SCL Science is also dedicated to building a digital healthcare ecosystem using artificial intelligence and high-quality medical data. Its services extend to clinical trial analysis, bio-logistics, and an expanding drug discovery platform focused on AI-driven cancer vaccine development. The company serves hospitals, research laboratories, and other medical institutions.

Recent filings

Filing Released Lang Actions
[기재정정]분기보고서 (2024.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'SCL Science Inc.' covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial statements, management analysis, and corporate governance information. Although it includes a 'Correction' (정정) section at the beginning, the document itself is the full quarterly report, not just an announcement of one. Therefore, it is classified as an Interim/Quarterly Report. Q1 2024
2024-08-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as an 'Insider Trading Report' or 'Director's Dealing' report) where company executives or major shareholders disclose their shareholdings or changes in their holdings. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2024-07-25 Korean
주주총회소집결의 (임시주주총회)
AGM Information Classification · 1% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for SCL Science, detailing the date, location, and agenda items (appointment of directors). This type of document is a standard proxy solicitation or meeting notice sent to shareholders to inform them of upcoming voting matters. Given the specific categories provided, 'PSI' (Proxy Solicitation & Information Statement) is the most accurate classification for a notice of a shareholder meeting and its agenda.
2024-07-24 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date for an upcoming Extraordinary General Meeting (EGM). It does not contain the full proxy materials or the meeting results themselves, but rather serves as a formal notice of the shareholder record date. Given the nature of the filing as a standard regulatory disclosure regarding corporate governance and meeting preparation, it falls under the general regulatory filing category.
2024-07-24 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the period ending March 31, 2024, submitted to the Financial Supervisory Service and Korea Exchange. It contains detailed corporate information, financial statements, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-14 Korean
합병등종료보고서(자산양수도)
M&A Activity Classification · 1% confidence The document is a 'Report on the Completion of Merger, etc.' (합병등종료보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the finalization of a tangible asset transfer (real estate) between SCL Science and U-Bat. While the title mentions 'merger', the content specifically describes the completion of a major asset disposal/transfer. In the context of corporate filings, this is a regulatory disclosure regarding the completion of a previously announced material transaction. Since it is a formal regulatory filing reporting the conclusion of a specific corporate event, it falls under the 'Regulatory Filings' category.
2024-04-25 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.